The report provides a detailed analysis essential for establishing an Erdafitinib production plant. It encompasses all critical aspects necessary for Erdafitinib production, including the cost of Erdafitinib production, Erdafitinib plant cost, Erdafitinib production costs, and the overall Erdafitinib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Erdafitinib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Erdafitinib is a small-molecule anticancer drug that is mainly used in the treatment of certain types of advanced cancers. It is primarily used for the treatment of patients with urothelial carcinoma, including bladder cancer, who have specific genetic alterations in the FGFR (fibroblast growth factor receptor) pathway.
The drug works by blocking abnormal FGFR signalling, which helps slow down or stop the growth of cancer cells. It is also used when the disease has progressed after standard chemotherapy or when other treatment options are limited. It is mainly used for patients with specific genetic mutations in FGFR genes, and it is usually prescribed when other treatments have not worked. It is taken orally and helps slow down or stop the spread of cancer cells in the body. It supports targeted cancer therapy by focusing on tumours with known genetic mutations. In addition, Erdafitinib is used in oncology research to better understand FGFR-driven cancers and to develop personalised treatment approaches.
The market for Erdafitinib is mainly driven by its application as a part of personalised cancer therapy, which fuels its demand in the oncology sector. Its application as an anti-cancer medication for the treatment of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 or FGFR2 genetic alterations also boosts its demand in the pharmaceutical industry.
Its application as targeted cancer therapy has significantly contributed to its rising demand in the oncology and pharmaceutical industries. Its application as a reference compound in oncology research to study FGFR genetic alterations and develop improved treatments also strengthens its demand in the medical research and biotechnology sectors. Additionally, industrial Erdafitinib procurement depends on factors such as the cost and availability of key raw materials, regulatory approvals across different regions, and compliance with pharmaceutical safety standards. Moreover, developments in precision medicine, reliability of suppliers, clinical trial outcomes, and efficient distribution networks also impact procurement processes for this high-value therapeutic product.
Raw Material for Erdafitinib Production
According to the Erdafitinib production plant project report, the major raw materials for Erdafitinib production include 3,5-Dimethoxyaniline, 2-Bromoethylamine Hydrobromide, and 7-Bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline.
Production Process of Erdafitinib
The extensive Erdafitinib production cost report consists of the following industrial production process:
- Production via Chemical Synthesis: The production process of Erdafitinib begins with the use of 3,5-dimethoxyaniline and 2-bromoethylamine hydrobromide as main starting materials. These are transformed into the major intermediate N1-(3,5-dimethoxyphenyl)-N2-isopropylethane-1,2-diamine through a novel two-step process. Then, this intermediate is coupled with 7-bromo-2-(1-methyl-1H-pyrazol-4-yl)quinoxaline to directly produce high-purity Erdafitinib as the final product.
Erdafitinib is a pan-fibroblast growth factor receptor tyrosine kinase inhibitor. It appears as a yellow powder that is practically insoluble or insoluble in aqueous media over a wide range of pH values, but freely soluble in organic solvents. The molecular formula of the compound is C25H30N6O2, and its molecular mass is 446.56 g/mol. It has a density of approximately 1.20 g/cm³, and its melting point ranges from 136 to 140 degree Celsius. The boiling point is approximately 662.3 degree Celsius. Erdafitinib is formulated as film-coated tablets for oral administration in strengths of 3 mg, 4 mg, and 5 mg. The compound should be stored at room temperature between 20 degree Celsius and 25 degree Celsius with excursions permitted between 15 degree Celsius and 30 degree Celsius. It is known to cause serious adverse effects, including ocular disorders such as inflamed eyes, inflamed cornea, and retinal disorders, as well as hyperphosphatemia. It is recommended that patients undergo regular eye examinations and serum phosphate monitoring during treatment. Extended exposure to this substance may cause serious health problems such as hepatotoxicity and embryo-fetal toxicity.
